Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Matthew Zorn's New Role: Attorney Matthew Zorn, known for his advocacy in cannabis and psychedelics policy, has been appointed as Deputy General Counsel at the U.S. Department of Health and Human Services, focusing on psychedelics policy, marking a significant shift from litigation to federal policymaking.
Impact on Psychedelics Research: Zorn's appointment is expected to enhance support for psychedelic-assisted therapy, particularly for veterans, as the new administration prioritizes exploring the therapeutic potential of psychedelics, with recent statements from the FDA and VA indicating positive outcomes from related studies.
Trade with 70% Backtested Accuracy
Analyst Views on PSIL
About the author
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Clinical Trial Success: Quantum Biopharma Ltd.'s subsidiary, Huge Biopharma Australia, has received a clinical study report confirming that its compound Lucid-MS is safe and tolerable in healthy adults, allowing for further development towards treating multiple sclerosis.
Stock Performance: Following the positive trial results, QNTM stock has seen significant growth over the past year, although it experienced an 8.63% decline recently, trading at $25.40.
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Matthew Zorn's New Role: Attorney Matthew Zorn, known for his advocacy in cannabis and psychedelics policy, has been appointed as Deputy General Counsel at the U.S. Department of Health and Human Services, focusing on psychedelics policy, marking a significant shift from litigation to federal policymaking.
Impact on Psychedelics Research: Zorn's appointment is expected to enhance support for psychedelic-assisted therapy, particularly for veterans, as the new administration prioritizes exploring the therapeutic potential of psychedelics, with recent statements from the FDA and VA indicating positive outcomes from related studies.
5 ETFs That Beat Market Turmoil With Gains Last Week
Market Volatility and Economic Indicators: Wall Street experienced volatility due to disappointing tech earnings, mixed labor data, and rising inflation fears, with gold prices reaching record highs as a safe haven investment.
Top Performing ETFs: Five ETFs showed gains amidst the market uncertainty, including Direxion Daily PLTR Bull 2X Shares (78.82% gain) and AdvisorShares Psychedelics ETF (21.61% gain), highlighting sectors like technology and psychedelics.
Why Is Penny Stock Clearmind Gaining Today?
Clearmind Medicine's Clinical Trial Approval: Clearmind Medicine Inc. received IRB approval for its Phase I/IIa clinical trial of CMND-100, a drug aimed at treating alcohol use disorder (AUD), which will be conducted at Yale School of Medicine.
Market Reaction and Potential Impact: Following the announcement, CMND shares rose by 35% to $1.64, highlighting investor interest in the potential for CMND-100 to improve treatment options for AUD, addressing a significant health issue responsible for millions of deaths annually.
The Zacks Analyst Blog Highlights AdvisorShares Psychedelics ETF, Simplify Volt Robocar Disruption and Tech ETF, First Trust SkyBridge Crypto Industry & Digital Economy ETF, U.S. Global Jets ETF and First Trust NASDAQ ABA Community Bank Index Fund
ETFs Featured: Zacks.com highlights several top-performing ETFs, including AdvisorShares Psychedelics ETF, Simplify Volt Robocar Disruption and Tech ETF, and First Trust SkyBridge Crypto Industry & Digital Economy ETF, amidst fluctuating market conditions influenced by inflation and Federal Reserve policies.
Market Outlook: The anticipation of a second Trump administration is expected to boost stocks due to market-friendly policies, while the Federal Reserve's recent interest rate cuts aim to stimulate economic growth despite concerns about inflation.
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
- FDA Panel Rejects MDMA for PTSD Treatment: A panel of FDA advisors rejected the use of MDMA in treating post-traumatic stress disorder (PTSD) due to lack of evidence that benefits outweigh risks.
- Stocks in Psychedelic Space Decline: Following the ruling, many stocks in the psychedelic space, such as Cybin Inc, Mind Medicine, and ATAI Life Sciences, experienced declines.
- Impact on Market: The AdvisorShares Psychedelics ETF also traded lower after the ruling, reflecting a negative sentiment in the industry.
- Future Implications: While the FDA is not bound by the advisory board's decision, the ruling is seen as a setback in approving and regulating psychedelic treatments.
- Advocates' Perspective: Proponents argue that psychedelic drugs may offer more effective mental health treatments compared to existing options on the market.
Quantum Biopharma Reports Positive Phase 1 Safety For Multiple Sclerosis Drug
Clinical Trial Success: Quantum Biopharma Ltd.'s subsidiary, Huge Biopharma Australia, has received a clinical study report confirming that its compound Lucid-MS is safe and tolerable in healthy adults, allowing for further development towards treating multiple sclerosis.
Stock Performance: Following the positive trial results, QNTM stock has seen significant growth over the past year, although it experienced an 8.63% decline recently, trading at $25.40.
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Matthew Zorn's New Role: Attorney Matthew Zorn, known for his advocacy in cannabis and psychedelics policy, has been appointed as Deputy General Counsel at the U.S. Department of Health and Human Services, focusing on psychedelics policy, marking a significant shift from litigation to federal policymaking.
Impact on Psychedelics Research: Zorn's appointment is expected to enhance support for psychedelic-assisted therapy, particularly for veterans, as the new administration prioritizes exploring the therapeutic potential of psychedelics, with recent statements from the FDA and VA indicating positive outcomes from related studies.
5 ETFs That Beat Market Turmoil With Gains Last Week
Market Volatility and Economic Indicators: Wall Street experienced volatility due to disappointing tech earnings, mixed labor data, and rising inflation fears, with gold prices reaching record highs as a safe haven investment.
Top Performing ETFs: Five ETFs showed gains amidst the market uncertainty, including Direxion Daily PLTR Bull 2X Shares (78.82% gain) and AdvisorShares Psychedelics ETF (21.61% gain), highlighting sectors like technology and psychedelics.
Why Is Penny Stock Clearmind Gaining Today?
Clearmind Medicine's Clinical Trial Approval: Clearmind Medicine Inc. received IRB approval for its Phase I/IIa clinical trial of CMND-100, a drug aimed at treating alcohol use disorder (AUD), which will be conducted at Yale School of Medicine.
Market Reaction and Potential Impact: Following the announcement, CMND shares rose by 35% to $1.64, highlighting investor interest in the potential for CMND-100 to improve treatment options for AUD, addressing a significant health issue responsible for millions of deaths annually.
The Zacks Analyst Blog Highlights AdvisorShares Psychedelics ETF, Simplify Volt Robocar Disruption and Tech ETF, First Trust SkyBridge Crypto Industry & Digital Economy ETF, U.S. Global Jets ETF and First Trust NASDAQ ABA Community Bank Index Fund
ETFs Featured: Zacks.com highlights several top-performing ETFs, including AdvisorShares Psychedelics ETF, Simplify Volt Robocar Disruption and Tech ETF, and First Trust SkyBridge Crypto Industry & Digital Economy ETF, amidst fluctuating market conditions influenced by inflation and Federal Reserve policies.
Market Outlook: The anticipation of a second Trump administration is expected to boost stocks due to market-friendly policies, while the Federal Reserve's recent interest rate cuts aim to stimulate economic growth despite concerns about inflation.
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
- FDA Panel Rejects MDMA for PTSD Treatment: A panel of FDA advisors rejected the use of MDMA in treating post-traumatic stress disorder (PTSD) due to lack of evidence that benefits outweigh risks.
- Stocks in Psychedelic Space Decline: Following the ruling, many stocks in the psychedelic space, such as Cybin Inc, Mind Medicine, and ATAI Life Sciences, experienced declines.
- Impact on Market: The AdvisorShares Psychedelics ETF also traded lower after the ruling, reflecting a negative sentiment in the industry.
- Future Implications: While the FDA is not bound by the advisory board's decision, the ruling is seen as a setback in approving and regulating psychedelic treatments.
- Advocates' Perspective: Proponents argue that psychedelic drugs may offer more effective mental health treatments compared to existing options on the market.
